Showing 1-10 of about 69 articles.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences Announces New Regulatory Approvals and Target Launch Dates for Three New Microcyn(R)-Based Products in Middle East Countries
PETALUMA, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced new regulatory approvals in Dubai, United Arab Emirates, Kuwait, and Iraq for three new Microcyn®-based consumer products: Face Cool™, a hydrogel for the treatment of acne and various dermatoses; Baby Cool™, a hydrogel for treatment of baby rash; and Lady Cool™, a feminine hygiene wash. All products are targeted to be launched in the fall of 2013.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based Products in Singapore and Malaysia
PETALUMA, Calif., April 10, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that the company's partner in that region, Dyamed Biotech Pte. Ltd, is initiating rollout of five new Microcyn® Technology-based products in Singapore and Malaysia, both in the hospital and consumer markets. The five products, which include Dermacyn™ BabyGuard, Dermacyn DermaGuard, Dermacyn SkinGuard Solution, Dermacyn SkinGuard Hydrogel and Dermacyn Wound Care Hydrogel, will be rolled out sequentially with all products commercialized by year's end.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of Three New International Patents for Microcyn(R) Technology
PETALUMA, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced the issuance of three new international patents for the company's flagship technology, Microcyn®. These include a Chinese patent for treatment of second- and third-degree burns, and two Mexican patents, the first for treatment of skin ulcers and the second for treatment of second- and third-degree burns as well.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences Announces Reverse Split of Common Stock
PETALUMA, Calif., March 28, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, announced today that a 1-for-7 reverse split of its common stock will be effective at the open of business on Monday, April 1, 2013. The reverse stock split was previously approved by the company's stockholders at the company's special meeting held on March 22, 2013. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split ratio to be a ratio of 1-for-7 on March 22, 2013.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study
PETALUMA, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective drugs, devices and nutritional products, including Microcyn® Technology solutions which are used in multiple markets including dermatology, post-surgical, wound care, and animal healthcare, today announced completion of the 112-day follow-up period in the company's clinical trial for the management of hypertrophic or keloid scars. The 40-patient comparative, double-blinded and randomized clinical study was based on an FDA-approved protocol. Patients were enrolled at four different U.S. clinical sites, including Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences Announces Closing of Public Offering of 8,625,000 Shares of Common Stock
PETALUMA, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective drugs, devices and nutritional products, today announced the closing of its underwritten public offering of 8,625,000 shares of common stock at an offering price of $0.40 per share, including 1,125,000 shares of its common stock to cover the over-allotment. Oculus received gross proceeds of $3.45 million.
Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Announces Full Exercise of Underwriters' Over-Allotment Option
PETALUMA, Calif., March 7, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 1,125,000 shares of common stock, at a public offering price of $0.40 per share in connection with its previously announced underwritten public offering of 7,500,000 shares of common stock, bringing total gross proceeds from the offering to approximately $3.5 million.
Showing 1-10 of about 69 articles.